Guanfacine

Introduction Overview

Generic Name

guanfacine

Brand Name

Intuniv

Dosage Form

Extended-release tablet

Drug Class

Antiadrenergic agents, centrally acting

Pharmacokinetics

Absorption: Guanfacine, administered as Intuniv extended-release tablets, is absorbed orally with kinetics influenced by food intake. High-fat meals can accelerate absorption, leading to increased peak plasma concentrations (Cmax) without significant alterations in total systemic exposure (area under the curve, AUC). Peak plasma concentrations are typically reached within 5 hours after administration of Intuniv, reflecting its extended-release formulation designed for once-daily dosing. The absorption profile allows for steady therapeutic plasma levels to be maintained with minimal fluctuation.

Distribution: Guanfacine is moderately distributed throughout the body, exhibiting an apparent volume of distribution (Vd) approximately 1.2-1.4 L/kg, suggesting distribution into total body water and some tissue penetration. It exhibits approximately 70% plasma protein binding, primarily to albumin, which influences its free active drug concentration. Guanfacine crosses the blood-brain barrier effectively, an important characteristic given its central nervous system (CNS) activity in attenuating sympathetic outflow. The drug has been detected in cerebrospinal fluid, indicating CNS penetration critical for its efficacy in ADHD treatment.

Metabolism: Guanfacine undergoes hepatic metabolism predominantly via the cytochrome P450 isoenzyme CYP3A4. Biotransformation includes oxidative metabolism leading to inactive metabolites. The extent of metabolism can be significantly influenced by CYP3A4 inhibitors or inducers, which may increase or decrease plasma guanfacine levels, respectively, requiring careful dose adjustment or monitoring. Additionally, guanfacine does not induce or inhibit major CYP enzymes substantially, minimizing complex drug-drug interactions.

Elimination: Guanfacine and its metabolites are primarily excreted renally, with approximately 50% to 60% of the administered dose eliminated in urine, mainly as metabolites. The elimination half-life ranges between 17 to 22 hours, supporting once-daily dosing schedules. Renal impairment can reduce clearance, potentially leading to increased plasma concentrations, indicating the need for cautious use or dose modification in patients with compromised renal function. Fecal excretion accounts for a minor elimination pathway. Steady-state plasma concentrations are typically achieved within 3 to 5 days, and dose adjustments should be spaced accordingly.

Dosage Forms

Available Dosage Forms: Intuniv is formulated as an extended-release (ER) oral tablet designed for once-daily administration. The tablets should be swallowed whole and not crushed, chewed, or broken to preserve the extended-release properties.

Dosage Strengths include:
- Intuniv ER tablets: 1 mg, 2 mg, 3 mg, 4 mg

Dosages for Adults and Adolescents: Intuniv is approved and primarily used in pediatric populations aged 6 to less than 18 years for attention deficit hyperactivity disorder (ADHD). Although adult use occurs off-label, dosing regimens should be individualized with cautious titration.

Pediatric Dosing for ADHD:
- Initial dose: 1 mg orally once daily, administered either in the morning or in the evening at approximately the same time each day.
- Dose increases: Incremental titration by no more than 1 mg per week.
- Target dose: Typically ranges from 0.05 to 0.12 mg/kg/day, with total daily doses between 1 mg and 7 mg depending on clinical response and tolerability.
- Maximum evaluated dose: For children 6 to 12 years, doses above 4 mg/day have not been sufficiently studied; for adolescents aged 13 to 17 years, doses above 7 mg/day have not been evaluated.

Specific Patient Populations:
- Renal impairment may necessitate dose adjustment due to decreased clearance.
- Patients with hepatic impairment require cautious use given hepatic metabolism involvement.
- Dose adjustments may be required based on the patient's weight, particularly in pediatric patients, to optimize therapeutic effect and minimize adverse events.
- Intuniv is not approved for use in children under 6 years of age.

Clinical Guidelines recommend administration of Intuniv at bedtime to minimize daytime somnolence. Consistency in dosing time is emphasized to maintain steady plasma drug concentrations. Avoidance of high-fat meals around dosing is advised to reduce increased absorption rates that may alter drug pharmacodynamics.

Mechanism Of Action

Guanfacine, the active component of Intuniv, is a selective alpha-2A adrenergic receptor agonist that acts centrally on the locus coeruleus and prefrontal cortex to modulate noradrenergic neurotransmission. By stimulating these inhibitory presynaptic receptors, guanfacine reduces sympathetic nerve impulses, which in turn decreases adrenergic tone affecting both cardiovascular regulation and cognitive functions.

At a molecular level, guanfacine's activation of postsynaptic alpha-2A receptors enhances functional connectivity and signaling within the prefrontal cortex by strengthening the regulation of attention, impulse control, and working memory. This mechanism is hypothesized to underpin its efficacy in reducing ADHD symptoms. The drug modulates cyclic AMP (cAMP) pathways inside neurons, leading to the closure of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and thus increasing the strength of prefrontal cortical networks critical for cognitive control.

In cardiovascular contexts, guanfacine centrally reduces sympathetic outflow resulting in vasodilation and lowered heart rate, contributing to its antihypertensive properties. This central sympatholytic effect decreases peripheral vascular resistance and, consequently, blood pressure.

Comparatively, guanfacine has a higher selectivity for the alpha-2A receptor subtype versus clonidine, another alpha-2 agonist, resulting in fewer sedative side effects and different clinical applications. Clinical trials demonstrate that while stimulants remain first-line agents for ADHD, guanfacine offers adjunctive or monotherapy options, particularly for patients who experience stimulant intolerance or require extended symptom control through non-stimulant mechanisms.

Pharmacological Actions

Selective agonist of central alpha-2A adrenergic receptors, reducing sympathetic outflow.
Modulation of prefrontal cortex neuronal activity leading to improved attention, working memory, and impulse control.
Central nervous system depressant effects that decrease nerve impulses to the heart and blood vessels.
Antihypertensive effects via vasodilation and reduced peripheral vascular resistance.
Prolonged action due to extended-release formulation allowing once-daily dosing.
Minimal direct cardiac depressant activity but results in decreased heart rate through central mechanisms.
Reduction of hyperactivity and impulsivity symptoms in ADHD through neuromodulation.
Adjunctive effects when combined with stimulant medications for enhanced ADHD symptom control.
Influence on cyclic AMP signaling pathways inside neurons to stabilize prefrontal cortical networks.
CNS sedative and calming effects which can reduce anxiety and agitation in some patients.
Limited respiratory depressive effects compared to other centrally acting agents.
Improvement of executive function deficits in neuropsychiatric disorders.
Does not significantly induce or inhibit major cytochrome P450 enzymes, limiting drug-drug interactions.
Demonstrated efficacy for both monotherapy and adjunctive treatment in pediatric ADHD.
Extended-release profile reduces fluctuations in plasma drug levels, improving tolerability.

Therapeutic Or Clinical Uses

Treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older.
Monotherapy for ADHD symptom management in pediatric populations.
Adjunctive therapy to stimulant medications in ADHD treatment to improve attention and reduce hyperactivity.
Off-label use in management of hypertension under the brand name Tenex.
Control of impulsivity and hyperactivity symptoms in ADHD patients who are intolerant to stimulants.
Management of sleep disturbances associated with ADHD due to sedative effects.
Potential use in neuropsychiatric disorders requiring modulation of noradrenergic systems.
Reducing oppositional symptoms when combined with behavioral therapy in ADHD.
Adjunct treatment in children with coexisting disorders such as tics or anxiety disorders.
Improvement of executive function deficits related to prefrontal cortex dysfunction.
Reduction of sympathetic nervous system overactivity-related cardiovascular symptoms.
Alternative treatment option for patients with contraindications to stimulant medications.
Facilitation of blood pressure lowering in patients with comorbid hypertension and ADHD (Tenex formulation).
May support behavioral control in patients with ADHD comorbid mood instability.
Potential off-label applications in certain sleep disorders due to sedative and antihypertensive effects.

Side Or Adverse Effects

Drowsiness or excessive sedation, especially during initial dose titration.
Dizziness and light-headedness due to blood pressure lowering effects.
Hypotension with symptoms such as fainting or feeling faint.
Bradycardia or slow heart rate, potentially leading to fatigue or syncope.
Dry mouth commonly reported by patients taking guanfacine.
Constipation and gastrointestinal discomfort including nausea and abdominal pain.
Irritability, fatigue, and weakness unrelated to sedation in some patients.
Headache, sometimes occurring as a rebound symptom upon abrupt discontinuation.
Sleep disturbances such as insomnia or vivid dreams during dose adjustment.
Possible anxiety or nervousness, especially in the pediatric population.
Hallucinations reported rarely, primarily in children with neurological vulnerabilities.
Withdrawal symptoms including rapid heartbeats, increased blood pressure, tremors, and confusion if stopped abruptly.
Rare allergic reactions presenting as rash, hives, or swelling of face and throat.
Potential for exacerbation of preexisting cardiac conduction abnormalities.
Transient elevation of liver enzymes reported anecdotally; monitoring may be warranted.

Precautions

Use caution when administering to patients with preexisting cardiovascular disease, including coronary artery disease or arrhythmias.
Monitor blood pressure and heart rate regularly to detect hypotension or bradycardia.
Avoid sudden discontinuation to prevent withdrawal symptoms and rebound hypertension.
Advise patients about potential sedation and avoid operating machinery or driving until the drug's effects are known.
Exercise caution in patients with renal or hepatic impairment as pharmacokinetics may be altered.
Recognize that dosing in children should consider body weight and adjustments made accordingly.
Avoid concomitant use with other CNS depressants unless under strict medical supervision due to additive sedation.
In patients with a history of stroke or cerebrovascular disease, monitor neurological status closely.
Evaluate for possible interactions with other antihypertensive agents when used for blood pressure control.
Instruct patients to avoid alcohol consumption to minimize enhanced sedative effects.
Screen for contraindications including known allergy to guanfacine components.
Inform parents and caregivers about the importance of adherence and avoiding missed doses.
Use with caution during pregnancy; benefits and risks should be carefully weighed.
Breastfeeding mothers should consult healthcare providers on risks of drug transmission via breast milk.
Regular follow-up evaluations are necessary to assess efficacy, side effects, and growth parameters in pediatric patients.

Warnings

Risk of severe hypotension and bradycardia especially in overdose or when combined with other antihypertensive agents.
Potential for significant sedation leading to impairment of mental alertness and physical coordination.
Avoid use in patients with a history of hypersensitivity or allergic reactions to guanfacine.
Abrupt cessation may cause rebound hypertension, tachycardia, agitation, headache, and seizures.
Increased sensitivity to heat and risk of hyperthermia; advise against overheating or dehydration during exercise or hot weather.
May exacerbate depressive symptoms or cause mood changes; monitor patients closely.
Concurrent use with other CNS depressants (e.g., benzodiazepines, opioids) may potentiate sedation and respiratory depression.
Use with caution in patients with renal or hepatic impairment due to altered drug clearance.
Pregnancy and nursing risks are not fully determined; avoid use unless clearly warranted.
Hypotension and syncope risk necessitate caution when initiating or increasing dose, especially in elderly or debilitated patients.
Report any signs of infection or unusual bleeding promptly, as the drug may rarely affect immune parameters.
Children may experience hallucinations or psychotic symptoms; vigilance required during therapy.
Patients should be warned about potential dizziness upon standing (orthostatic hypotension).
Close monitoring is crucial in patients with cardiovascular disease to avoid adverse outcomes.
Use with caution in patients predisposed to seizure disorders; monitor for changes in seizure frequency.

Contraindication

Known hypersensitivity or allergic reaction to guanfacine or any component of the Intuniv formulation.
Children younger than 6 years of age due to lack of safety and efficacy data.
Concomitant use with drugs that may dangerously amplify hypotensive effects without medical supervision.
Absolute contraindication in patients with severe bradycardia or atrioventricular block without pacemaker support.
Severe hepatic impairment where metabolism of guanfacine may be significantly compromised.
Known intolerance to extended-release formulations requiring alternate therapy.
Concurrent administration during procedures requiring general anesthesia without thorough cardiovascular assessment.
Patients with unstable cardiovascular conditions such as recent myocardial infarction or uncontrolled arrhythmias.
Patients with untreated severe hypotension or hypovolemia.
Presence of acute stroke or cerebrovascular accident where sympathetic regulation is critical.
Use in conditions where CNS depressants are contraindicated due to risk of profound sedation.
Patients with narrow-angle glaucoma due to possible changes in intraocular pressure.
Known severe renal impairment with inability to monitor drug levels or effects closely.
Contraindicated if patient unable to swallow tablets whole due to release profile requirements.
Hypersensitivity to similar centrally acting alpha-2 adrenergic agonists.

Drug Interactions

Coadministration with CYP3A4 inhibitors such as ketoconazole may increase guanfacine plasma concentrations, raising risk of adverse effects.
CYP3A4 inducers like phenobarbital can decrease guanfacine levels, reducing therapeutic efficacy.
Additive CNS depressant effects with sedatives, benzodiazepines (e.g., Valium, Xanax), opioids, and muscle relaxants increasing sedation and respiratory depression risk.
Enhanced hypotensive effects when used concomitantly with other antihypertensive agents, necessitating blood pressure monitoring.
Potential interaction with medications for mental illness that influence central nervous system activity.
Drugs that prolong cardiac conduction may interact to exacerbate bradycardia or heart block.
Alcohol consumption increases CNS depression and hypotensive effects.
Co-use with stimulants in ADHD treatment requires careful dose titration to balance opposing pharmacodynamic effects.
Avoid abrupt discontinuation when combined with beta-blockers due to complex cardiovascular effects.
Anticholinergic drugs may exacerbate constipation associated with guanfacine.
Drugs altering gastrointestinal motility could influence guanfacine absorption.
Herbal products like St. John's Wort may induce CYP enzymes, reducing guanfacine effectiveness.
Concurrent use with lithium or other psychotropic agents should be monitored for increased side effects.
Use caution when combined with drugs causing QT interval prolongation, although guanfacine itself has minimal QT effects.
Interactions with antihistamines may increase sedation and impair cognitive function.

Preparations Of The Drug

Intuniv extended-release oral tablets available in 1 mg, 2 mg, 3 mg, and 4 mg strengths.
Formulated as an extended-release tablet to allow once-daily dosing with consistent plasma levels.
Tablets are film-coated and designed to be swallowed whole; crushing or chewing is contraindicated.
Available as prescription-only medication with no generic equivalents widely marketed as of current approval status.
Packaging designed to protect from moisture, heat, and light; store at controlled room temperature.
Patient information leaflets provided for education on dosing, side effects, and precautions.
Prescribing information includes detailed titration schedules and contraindications.
Different from the Tenex formulation, which is immediate-release guanfacine used for hypertension.
Manufactured under strict quality controls to ensure bioequivalence and therapeutic consistency.
Available in blister packs or bottles, depending on dispensing pharmacy preferences.
Provided with medication guides emphasizing avoidance of sudden dose changes and interaction precautions.
Includes labeling for careful use in pediatric populations with dose adjustments based on weight.
Not formulated as injections, suspensions, or other dosage forms for this indication.
Supply chains include specialty pharmacies and hospital formulary availability.
Dosing administration recommendations include taking at bedtime with or without food, avoiding high-fat meals.